CNS disorders are on the rise despite advancements in our understanding of their
pathophysiological mechanisms. A major hurdle to the treatment of these disorders is the …

Activation of Mechanistic target of rapamycin (mTOR) signaling plays a crucial role in
tumorigenesis of numerous malignancies including glioblastoma (GB). The Canonical …

Background The cardiovascular complications of cancer therapeutics are the focus of the
burgeoning field of cardio‐oncology. A common challenge in this field is the impact of …

Glioblastoma, a rare, and highly lethal form of brain cancer, poses significant challenges in
terms of therapeutic resistance, and poor survival rates for both adult and paediatric patients …

Abstract Activation of PI3K/Akt/mTOR (mechanistic target of rapamycin) signaling cascade
has been shown in tumorigenesis of numerous malignancies including glioblastoma (GB) …

In addition to each of the factors that govern the identification of a successful oncology drug
candidate, drug discovery aimed at treating neurological cancer must also consider the …

Glioblastoma multiforme is the most malignant and aggressive type of brain tumor, with a
mean life expectancy of less than 15 months. This is due in part to the high resistance to …

A phase I trial of an engineered poliovirus for the treatment of recurrent glioblastoma (GBM)
has attracted attention due to 8 survivors reaching the 24-month and 5 reaching the 36 …

The mammalian Target of Rapamycin (mTOR) is a molecular complex equipped with kinase
activity which controls cell viability being key in the PI3K/PTEN/Akt pathway. mTOR acts by …

Glioblastoma exhibits high mortality rates due to challenges with drug delivery to the brain
and into solid tumors. This two-pronged barrier necessitates high doses of systemic …